ASCO GU 2020: VEGF Tyrosine Kinase Inhibitors Show Activity After Combination Immunotherapy for Metastatic Renal Cell Carcinoma
Data on VEGF tyrosine kinase inhibitors after progression with immunotherapy have been limited.
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Renal Cell Carcinoma Center of Excellence
Visit our Renal Cell Carcinoma Center of Excellence for additional, in-depth coverage.